Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Daiichi Sankyo Company, Limited
  6. News
  7. Summary
    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Daiichi Sankyo Company, Limited Announces Results from the Multinational, Randomized, Controlled, Phase 3b ENVISAGE-TAVI AF Study

08/30/2021 | 02:31am EDT

Daiichi Sankyo Company, Limited has announced the results from the multinational, randomized, controlled, phase 3b ENVISAGE-TAVI AF study, comparing the efficacy and safety of edoxaban with vitamin-K-antagonists (VKAs) in patients with atrial fibrillation (AF) having undergone successful transcatheter aortic valve implantation (TAVI). Findings from the trial were presented at a Hot-Line session at ESC Congress 2021, organized by the European Society of Cardiology, and simultaneously published in The New England Journal of Medicine (NEJM). In ENVISAGE-TAVI AF, 1,426 elderly patients with multiple comorbidities were included and followed for up to three years. The study results suggest that edoxaban is an appropriate treatment option for AF patients with severe aortic stenosis following successful TAVI.1,2 To date, this is the only sufficiently large and statistically powered study that compares a non-vitamin K oral anticoagulant (NOAC) with VKAs in AF patients after TAVI. The study met its primary endpoint of edoxaban being noninferior to VKAs for the composite of net adverse clinical events (NACE), which included all-cause mortality, myocardial infarction, ischemic stroke, systemic thromboembolism, valve thrombosis, and International Society on Thrombosis and Haemostasis (ISTH)-defined major bleeding. NACE occurred in 170 edoxaban-treated patients (17.3% per year) and, similarly, in 157 VKA-treated patients (16.5% per year). Edoxaban also showed numerically lower rates of all-cause mortality and ischemic stroke (two of the six individual clinical events included in the composite of NACE): All-cause mortality occurred in 85 edoxaban-treated patients and 93 VKA-treated patients (7.8% versus 9.1% per year, respectively). Ischemic stroke occurred in 22 edoxaban-treated patients and 28 VKA-treated patients (2.1% versus 2.8% per year, respectively). The study did not meet its primary safety endpoint of ISTH-defined major bleeding, due to more gastrointestinal (GI) bleeds in the edoxaban arm.1,2 Other major bleeding events, including intracranial hemorrhage (ICH), as well as fatal and life-threatening bleeds, were similarly rare in both the edoxaban and VKA treatment arms: Major bleeding occurred in 98 edoxaban-treated patients and 68 VKA-treated patients (9.7% versus 7.0% per year, respectively).


ę S&P Capital IQ 2021
All news about DAIICHI SANKYO COMPANY, LIMITED
10/25ASTRAZENECA : Daiichi Sankyo in Clinical Trial Collaboration to Evaluate Datopotamab Derux..
MT
10/25Daiichi Sankyo Company, Limited and AstraZeneca Announces Second Clinical Trial Collabo..
CI
10/21Daiichi Sankyo Announces Development Progress of mRNA COVID-19 Vaccine in Japan
CI
10/21SHIONOGI : Japan's Shionogi starts Phase II/III clinical trial for new COVID-19 vaccine
RE
10/18Nikkei 225 Edges Down 0.2% on Profit-Taking, Energy Outlook
MT
10/13PRESS RELEASE : Defence Therapeutics Inc.: DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO ..
DJ
10/11DAIICHI SANKYO : Corporate Governance Report
PU
10/05DAIICHI SANKYO : Astrazeneca - Enhertu granted Breakthrough Therapy Designation in US for ..
AQ
10/04Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca Receive Gra..
CI
10/04ASTRAZENECA : Daiichi Sankyo's Enhertu Gets US FDA Breakthrough Therapy Tag for Breast Can..
MT
More news
Financials
Sales 2022 1 004 B 8 815 M 8 815 M
Net income 2022 58 600 M 515 M 515 M
Net cash 2022 624 B 5 485 M 5 485 M
P/E ratio 2022 95,0x
Yield 2022 0,93%
Capitalization 5 528 B 48 573 M 48 551 M
EV / Sales 2022 4,89x
EV / Sales 2023 4,60x
Nbr of Employees 16 033
Free-Float 97,6%
Chart DAIICHI SANKYO COMPANY, LIMITED
Duration : Period :
Daiichi Sankyo Company, Limited Technical Analysis Chart | 4568 | JP3475350009 | MarketScreener
Technical analysis trends DAIICHI SANKYO COMPANY, LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 2 884,00 JPY
Average target price 3 753,57 JPY
Spread / Average Target 30,2%
EPS Revisions
Managers and Directors
Sunao Manabe President, CEO & Representative Director
Hiroyuki Okuzawa CFO, Director, Executive Officer & Head-Management
Ken Takeshita Global Director-Research & Development
Noritaka Uji Independent Outside Director
Tsuguya Fukui Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
DAIICHI SANKYO COMPANY, LIMITED-18.42%47 906
JOHNSON & JOHNSON4.04%436 334
ROCHE HOLDING AG15.84%338 387
NOVO NORDISK A/S60.69%244 467
PFIZER, INC.18.34%244 227
ELI LILLY AND COMPANY48.17%225 231